Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.58 |
| ▸ | PIM1 | P11309 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MPO | P05164 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TERT | O14746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21433684 | 0.83 | MAPT (0.61) | MAPTALDH1A1GAAP2RX7CYP3A4 | |
| SCHEMBL2553539 | 0.82 | ALDH1A1 (0.57) | MAPTALDH1A1GAAP2RX7PIM1 | |
| SCHEMBL2552126 | 0.82 | ALDH1A1 (0.57) | MAPTALDH1A1GAAP2RX7PIM1 | |
| SCHEMBL4728279 | 0.77 | ALDH1A1 (0.47) | MAPTALDH1A1GAAP2RX7CYP3A4 | |
| SCHEMBL1142172 | 0.77 | P2RX7 (0.74) | MAPTALDH1A1GAAP2RX7CYP3A4 | |
| SCHEMBL2551255 | 0.76 | ALDH1A1 (1.00) | MAPTALDH1A1GAAP2RX7CYP1A2 | |
| Water SCHEMBL10373155 | 0.75 | ALDH1A1 (0.96) | MAPTALDH1A1GAAP2RX7CYP1A2 | |
| SCHEMBL14610232 | 0.75 | PIM1 (0.68) | ALDH1A1PIM1KDM4EADORA3KMT2A | |
| SCHEMBL4730799 | 0.74 | P2RX7 (0.45) | MAPTALDH1A1GAAP2RX7PIM1 | |
| SCHEMBL4729625 | 0.74 | P2RX7 (0.45) | MAPTALDH1A1GAAP2RX7CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0544662-A1 | ENZYME AMPLIFIED LANTHANID CHELATE LUMINESCENCE ASSAY. | KRONEM SYSTEMS INC (CA) | 1993-06-09 | — | — | EP | claimed |
| WO-1991008490-A1 | ENZYME AMPLIFIED LANTHANID CHELATE LUMINESCENCE ASSAY | KRONEM SYSTEMS INC. (CA) | 1991-06-13 | — | — | WO | claimed |
| EP-3774770-B1 | NOVEL HYDRAZONE DERIVATIVES FOR PREVENTING OR TREATING EBV-RELATED CANCERS | UNIV BRETAGNE OCCIDENTALE (FR) | 2023-09-06 | — | — | EP | disclosed |
| US-11406631-B2 | Hydrazone derivatives for preventing or treating EBV-related cancers | UNIVERSITE DE BRETAGNE OCCIDENTALE | 2022-08-09 | — | — | US | disclosed |
| US-20210161887-A1 | Novel Hydrazone Derivatives For Preventing Or Treating EBV-Related Cancers | UNIVERSITE DE BRETAGNE OCCIDENTALE (FR) | 2021-06-03 | — | — | US | disclosed |
| EP-3774770-A1 | NOVEL HYDRAZONE DERIVATIVES FOR PREVENTING OR TREATING EBV-RELATED CANCERS | Université de Bretagne Occidentale (FR) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019193071-A1 | NOVEL HYDRAZONE DERIVATIVES FOR PREVENTING OR TREATING EBV-RELATED CANCERS | UNIVERSITE DE BRETAGNE OCCIDENTALE (FR) | 2019-10-10 | — | — | WO | disclosed |
| EP-3549938-A1 | NOVEL HYDRAZONE DERIVATIVES FOR PREVENTING OR TREATING EBV-RELATED CANCERS | Université de Bretagne Occidentale (FR) | 2019-10-09 | — | — | EP | disclosed |
| EP-0544662-B1 | ENZYME AMPLIFIED LANTHANIDE CHELATE LUMINESCENCE ASSAY | KRONEM SYSTEMS INC (CA) | 1996-09-18 | — | — | EP | disclosed |
| US-5262299-A | Salicyl phosphate substrates, high sensitivity | KRONEM SYSTEMS, INC. (CA) | 1993-11-16 | — | — | US | disclosed |
| EP-0544662-A1 | ENZYME AMPLIFIED LANTHANID CHELATE LUMINESCENCE ASSAY. | KRONEM SYSTEMS INC (CA) | 1993-06-09 | — | — | EP | disclosed |
| WO-1991008490-A1 | ENZYME AMPLIFIED LANTHANID CHELATE LUMINESCENCE ASSAY | KRONEM SYSTEMS INC. (CA) | 1991-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210161887-A1 | Novel Hydrazone Derivatives For Preventing Or Treating EBV-Related Cancers | RB1, MALT1, NR3C1 | MAPT 3565/4885ALDH1A1 733/4885GAA 3530/4885 |
| US-11406631-B2 | Hydrazone derivatives for preventing or treating EBV-related cancers | RB1, MALT1, NR3C1 | MAPT 3439/4885ALDH1A1 826/4885GAA 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.